Assessment of iron absorption from a novel iron fortificant, FERRI PRO Trademark in an instant milk drink compared with ferrous sulphate in healthy adult females.

Massey University0 个研究点目标入组 24 人开始时间: 2015年7月2日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Healthy, non-anaemic, non-iron deficient (serum ferritin concentrations are > 12 ug/L and < 150 ug/L; haemoglobin > 120 g/L.
•Stable body weight and normal body mass index (18.5-25 kg/m2).
•Caucasian/European descent.
•C-reactive protein concentrations < 5 mg/L.

•History of gastrointestinal disorders including ulcers or gastrointestinal surgery.
•Established health problems likely to influence iron status such as inflammatory bowel disease, endocrine disorders, diabetes, celiac disease, red blood cell disorders, menorrhagia, haemorrhoids, haematuria or have had malaria.
•Donated blood or had significant blood loss during the 6 months prior to the study.
•Participated in a study involving administration of stable isotopes.
•Participated in another clinical trial during the three months leading up to the start of the study.
•Consumed antibiotics one month before the study and/or during the study.
•Be pregnant or have been pregnant in the 12 months prior to the study.
•Be breastfeeding.
•Regular consumers of iron supplements (define as >20 mg elemental iron at least 3-4 times per week for one month prior to the trial.
•Smoke cigarettes.
•Consume more than two units of alcohol per day.
•Vegetarian or vegan.
•Allergies to dairy products.
•On a controlled diet or dietary weight loss regimen within 4 weeks before and/or during the study.
•Experienced significant weight loss during the 6 months prior to the study.
•Taking any medications regularly, including antacids, except oral contraceptives.
•Have an aversion to blood sample collection.

发起方